MicroPort to Acquire Wright s OrthoRecon Business. June 19, 2013
|
|
- Randell Houston
- 5 years ago
- Views:
Transcription
1 MicroPort to Acquire Wright s OrthoRecon Business June 19, 2013
2 Forward-Looking Statements This presentation may contain forward-looking statements as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current view of future performance, results, and trends. Forward- looking statements may be identified by their use of terms such as anticipate, believe, could, estimate, expect, intend, may, plan, predict, project, will, and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The reader should not place undue reliance on forward-looking statements. Such statements are made as of the date of this presentation, and we undertake no obligation to update such statements after this date. As with all transactions, there is a risk that failure to obtain necessary approvals, or other intervening events, could prevent the transaction described in this presentation from closing, or could delay the closing. In addition, risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements are discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2012, and as may be supplemented in our Quarterly Reports on Form 10-Q). By way of example and without implied limitation, such risks and uncertainties include: failure to realize the anticipated financial and other benefits from the acquisition of BioMimetic Therapeutics, Inc. or a delay in realization thereof; failure to obtain, or a delay in obtaining, FDA approval of Augment Bone Graft, or a material limitation on the scope of such approval; lower than anticipated market acceptance of, or annual market demand for, Augment Bone Graft; future actions of the United States Attorney's office, the FDA, the Department of Health and Human Services or other U.S. or foreign government authorities, including those resulting from increased scrutiny under the Foreign Corrupt Practices Act and similar laws, that could delay, limit or suspend our development, manufacturing, commercialization and sale of products, or result in seizures, injunctions, monetary sanctions or criminal or civil liabilities; failure to obtain the FDA or other regulatory clearances needed to market and sell our products; any actual or alleged breach of the Corporate Integrity Agreement to which we are subject through September 2015 which could expose us to significant liability including exclusion from Medicare, Medicaid and other federal healthcare programs, potential criminal prosecution, and civil and criminal fines or penalties; adverse outcomes in existing product liability litigation; new product liability claims; inadequate insurance coverage; the possibility of private securities litigation or shareholder derivative suits; demand for and market acceptance of our new and existing products; potentially burdensome tax measures; recently enacted healthcare laws and changes in product reimbursement which could generate downward pressure on our product pricing; lack of suitable business development opportunities; inability to capitalize on business development opportunities; product quality or patient safety issues; challenges to our intellectual property rights; geographic and product mix impact on our sales; our inability to retain key sales representatives, independent distributors and other personnel or to attract new talent; inventory reductions or fluctuations in buying patterns by wholesalers or distributors; inability to realize the anticipated benefits of restructuring initiatives; negative impact of the commercial and credit environment on us, our customers and our suppliers; and the potentially negative effect of our ongoing compliance enhancements on our relationships with customers and our ability to deliver timely and effective medical education, clinical studies, and new products. 2
3 Use of Non-GAAP Financial Measures Wright Medical uses certain non-gaap financial measures in this presentation. Wright Medical uses non-gaap financial measures as supplemental measures of performance and believes these measures provide useful information to investors in evaluating our operations, period over period. However, non-gaap financial measures have limitations as analytical tools, and should not be considered in isolation or as a substitute for Wright Medical s financial results prepared in accordance with GAAP. In addition, investors should note that any non-gaap financial measures Wright Medical uses may not be the same non-gaap financial measures, and may not be calculated in the same manner, as that of other companies. 3
4 Today s Announcement Wright Medical Group, Inc. and MicroPort Scientific Corporation Enter Into Definitive Agreement Under Which MicroPort Will Acquire Wright s OrthoRecon Business Purchase price of $290 million in cash, subject to a net working capital adjustment Creates two distinct, separate, and focused businesses that are wellpositioned for growth OrthoRecon business will remain in Arlington and campus will become headquarters for MicroPort s global Orthopedic business Extremities-Biologics business including BioMimetic will continue as Wright Medical Expect to close by end of Q3 or early Q4 of
5 Rationale Transaction Transforms Wright Medical into High Growth Extremities and Biologics Pure Play and Expands Growth Opportunities for OrthoRecon Business OrthoRecon and Extremities - Biologics are two different businesses with distinctive and solid value propositions and unique paths for future growth Separation will enable both to be focused and strong in their respective markets and provide enhanced opportunities to accelerate their growth trajectory Each business will be better positioned to grow and help customers meet their needs though more focused attention and investment 5
6 Key Deal Terms Purchase price is $290 million, subject to a net working capital adjustment, payable in cash at closing Net after-tax proceeds, including transaction costs, are estimated to be ~$260 million Intend to use net proceeds to fund transition costs of $25 million to $35 million Remainder used to fund growth opportunities for the Extremities and Biologics business and pay certain retained liabilities of OrthoRecon business Transaction subject to customary closing conditions, including MicroPort shareholder approval and receipt of regulatory clearances Closing expected by end of 3Q or early 4Q of
7 MicroPort at A Glance MicroPort is a fast-growing, leading developer of interventional medical devices headquartered in Shanghai, China Relevant facts: 1,700 employees in 10 subsidiaries Traded on Hong Kong Exchange (HK: 0853), $1.1B market cap First China-based manufacturer of interventional cardiology products first developer and #1 market share leader in China for drug-eluting stents To learn more, visit 7
8 Why this buyer for Wright s OrthoRecon business? Product Portfolio Geographic Footprint Hip/Knee Hip/Knee Interventional Cardiology, Spine, Electrophysiology Orthopedic reconstruction Primarily China U.S., Europe, Japan, China, Brazil, India & Argentina No product portfolio overlap Small geographic footprint overlap 8
9 Key benefits for OrthoRecon business After the transition is complete, OrthoRecon will: Expand its customer base as MicroPort intends to leverage manufacturing and shipping facilities in Arlington to serve the needs of a large and rapidly growing Asian market Use European infrastructure to help grow MicroPort s Cardiovascular business in that geography Become headquarters for MicroPort s global Orthopedic business and continue to operate within its current, core markets Benefit from MicroPort s deep commitment to continued success of talented employee base, strong product portfolio, R&D expertise, global footprint 9
10 Key benefits for Extremities-Biologics As a smaller, high-growth Extremities company with breakthrough biologic opportunities, we will now be exclusively focused on: Accelerating growth opportunities in foot and ankle market to expand our current market lead Improving U.S. foot and ankle sales productivity Extending the global reach and penetration of Extremity products in key international markets Gaining U.S. regulatory approval for Augment Bone Graft 10
11 Following the Transaction Wright Medical expects to be well positioned and committed to accelerating growth in foot and ankle business, increasing U.S. foot and ankle sales productivity to $1 million per rep in 2014 Once Augment fully commercialized, anticipate company would be growing in excess of 20% Expect to be adjusted EBITDA positive in 2014, with opportunity for significant adjusted EBITDA growth in 2015 and beyond Extremity segment revenue guidance for 2013 of approx. $235 million to $240 million, which anticipates some potential minor, short-term dis-synergies as a result of the transaction Beginning in 2Q 13, OrthoRecon segment will be accounted for as discontinued operation in Wright s GAAP and non-gaap income statements Plan to update financial guidance and provide additional details on 2Q 13 conference call, which is currently scheduled for August 1,
12 Bright, exciting future for both businesses! This transaction is expected to create: A Win-Win scenario for both companies, and for each Wright business Two distinct, focused, and successful businesses that are well-positioned for growth Expanded growth opportunities for OrthoRecon business with deeply committed buyer who plans to invest in the business Smaller, high-growth pure play Extremities business focused on accelerating growth trajectory Enhanced ability to help our customers meet their needs though more focused attention from each business Seamless transition and continued success of OrthoRecon as part of MicroPort 12
13 For additional information, please contact: Julie Tracy Chief Communications Officer (901) NASDAQ: WMGI 13
14 MicroPort to Acquire Wright s OrthoRecon Business June 19, 2013
Jefferies 2014 Global Healthcare Conference. June 4, 2014
Jefferies 2014 Global Healthcare Conference June 4, 2014 1 Forward-Looking Statements This presentation may contain forward-looking statements as defined under U.S. federal securities laws, including statements
More informationZimmer Biomet Reports Second Quarter 2016 Financial Results
July 28, 2016 Zimmer Biomet Reports Second Quarter 2016 Financial Results -- Net Sales of $1.934 billion represent an increase of 65.6% over the prior year period, and an increase of 4.5% on an adjusted
More informationZimmer Biomet Reports Second Quarter 2017 Financial Results
Zimmer Biomet Reports Second Quarter 2017 Financial Results Jul 27, 2017 - Net sales of $1.954 billion for the second quarter represent an increase of 1.1% over the prior year period, and an increase of
More informationCombination Creates Leading Innovator in the Musculoskeletal Industry April 24, 2014
Combination Creates Leading Innovator in the Musculoskeletal Industry April 24, 2014 David Dvorak President and Chief Executive Officer Jim Crines EVP, Finance, and Chief Financial Officer Cautionary Statement
More informationMicroPort Scientific Corporation Announces HKEx Main Board Listing Details
MicroPort Scientific Corporation Announces HKEx Main Board Listing Details ******************************************************** Global Offering of 252,740,000 Shares At between HK$4.60 and HK$6.10
More informationjuly 2012 CEB to Acquire SHL Compelling Value Creation, Growth, and Scale Opportunity
july 2012 CEB to Acquire SHL Compelling Value Creation, Growth, and Scale Opportunity Safe Harbor Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2014
FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2014 Marlborough, Mass. (October 22, 2014) -- Boston Scientific Corporation (NYSE: BSX) generated sales of
More informationOrthofix Reports Second Quarter 2018 Financial Results
Orthofix Reports Second Quarter 2018 Financial Results August 6, 2018 Second Quarter Highlights Net sales of $111.5 million, an increase of 2.4% compared to prior year or 1.3% on a constant currency basis
More informationJULIO PORTALATIN President and CEO, Mercer
JULIO PORTALATIN President and CEO, Mercer Agenda Mercer at a Glance Accomplishments Well positioned for Growth Key Growth Initiatives 1 At a Glance 2013 Revenue $4.2 Billion A global leader in health,
More informationBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2013
FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2013 Fourth Quarter Marks Third Consecutive Quarter of Improved Performance Natick, Mass. (February
More informationBIOMET ANNOUNCES FIRST QUARTER OF FISCAL YEAR 2015 FINANCIAL RESULTS
BIOMET ANNOUNCES FIRST QUARTER OF FISCAL YEAR 2015 FINANCIAL RESULTS WARSAW, Ind., October 9, 2014 Biomet, Inc. ( the Company ) announced today financial results for its first quarter ended. First Quarter
More informationBIOMET ANNOUNCES SECOND QUARTER OF FISCAL YEAR 2015 FINANCIAL RESULTS
BIOMET ANNOUNCES SECOND QUARTER OF FISCAL YEAR 2015 FINANCIAL RESULTS WARSAW, Ind., January 6, 2015 Biomet, Inc. ( the Company ) announced today financial results for its second quarter ended. Second Quarter
More informationPlease note that the following presentation contains financial projections and other forward-looking statements that are specific to the date of the
Please note that the following presentation contains financial projections and other forward-looking statements that are specific to the date of the presentation July 16, 2012 and should not be considered
More informationBIOMET ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2014 PRELIMINARY FINANCIAL RESULTS
BIOMET ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2014 PRELIMINARY FINANCIAL RESULTS WARSAW, Ind., July 9, 2014 Biomet, Inc. ( the Company ) announced today preliminary financial results for its fourth quarter
More informationWuXi Biologics 2017 Interim Results
WuXi Biologics 2017 Interim Results August 2017 (Stock Code: 2269.HK) Forward-Looking Statements This presentation may contain certain forward-looking statements are not historical facts, but instead are
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers Baird Healthcare Conference, September 2017 NASDAQ: NOVT 1 Safe Harbor Statement The statements in this presentation
More informationBIOMET ANNOUNCES FIRST QUARTER OF FISCAL YEAR 2011 FINANCIAL RESULTS
BIOMET ANNOUNCES FIRST QUARTER OF FISCAL YEAR 2011 FINANCIAL RESULTS WARSAW, Ind., October 12, 2010 announced today financial results for its first fiscal quarter ended August 31, 2010. Net sales increased
More informationBIOMET ANNOUNCES SECOND QUARTER OF FISCAL YEAR 2013 FINANCIAL RESULTS
BIOMET ANNOUNCES SECOND QUARTER OF FISCAL YEAR 2013 FINANCIAL RESULTS WARSAW, Ind., January 8, 2013 Biomet, Inc. announced today financial results for its second fiscal quarter ended November 30, 2012.
More informationInvestor Presentation
Investor Presentation J.P. Morgan 36 th Annual Healthcare Conference San Francisco, CA January 2018 Forward-Looking Statements This presentation contains forward-looking statements (as defined in the Securities
More informationCowen and Company 38 th Annual Health Care Conference. March 13, 2018
Cowen and Company 38 th Annual Health Care Conference March 13, 2018 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute forward-looking
More informationInvestor Presentation. May 2018
Investor Presentation May 2018 Forward-Looking Statements This presentation contains forward-looking statements (as defined in the Securities Litigation Reform Act of 1995) regarding, among other things,
More informationBIOMET ANNOUNCES FIRST QUARTER OF FISCAL YEAR 2013 FINANCIAL RESULTS
BIOMET ANNOUNCES FIRST QUARTER OF FISCAL YEAR 2013 FINANCIAL RESULTS WARSAW, Ind., October 10, 2012 Biomet, Inc. announced today financial results for its first fiscal quarter ended August 31, 2012. Initial
More informationLHC Group and Almost Family: A Leading National Provider of In-Home Healthcare. November 16, 2017
LHC Group and Almost Family: A Leading National Provider of In-Home Healthcare November 16, 2017 Forward-Looking Statements This presentation contains forward looking statements (as defined in the Securities
More informationLHC GROUP AND ALMOST FAMILY ANNOUNCE MERGER OF EQUALS TO CREATE LEADING NATIONAL PROVIDER OF IN-HOME HEALTHCARE SERVICES
LHC GROUP AND ALMOST FAMILY ANNOUNCE MERGER OF EQUALS TO CREATE LEADING NATIONAL PROVIDER OF IN-HOME HEALTHCARE SERVICES National platform enables greater service and continuity across continuum of care
More information21st Annual Needham Growth Conference. January 16, 2019
21st Annual Needham Growth Conference January 16, 2019 1 Safe Harbor Statements made during this presentation that are forward-looking statements are based on current expectations and assumptions that
More informationOrthofix International N.V.
Orthofix International N.V. NASDAQ:OFIX Brad Mason - President & CEO Safe Harbor Statement Except for historical information contained herein, the statements made in this presentation constitute forward
More informationIQVIA Reports Fourth-Quarter and Full-Year 2017 Results, Issues First-Quarter and Full-Year 2018 Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More informationCredit Suisse Healthcare Conference. November 11, Dan Brennan, EVP & CFO
Credit Suisse Healthcare Conference November 11, 2014 Dan Brennan, EVP & CFO 1 Safe harbor for forward-looking statements This presentation contains forward-looking statements within the meaning of Section
More informationFOURTH QUARTER 2017 EARNINGS CALL FEBRUARY 27, 2018
FOURTH QUARTER 2017 EARNINGS CALL FEBRUARY 27, 2018 0 Agenda and Speakers Joe Woody Chief Executive Officer Halyard Outlook and Update on Divestiture 2018 Priorities Steve Voskuil Chief Financial Officer
More informationJune Investor Presentation
June 2014 Investor Presentation Safe Harbor Certain statements included herein, including guidance and those that express management's objectives and the strategies to achieve those objectives, as well
More informationBaird 2018 Global Healthcare Conference. September 5, 2018
Baird 2018 Global Healthcare Conference September 5, 2018 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute forward-looking statements,
More informationBIOMET ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2011 PRELIMINARY FINANCIAL RESULTS
BIOMET ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2011 PRELIMINARY FINANCIAL RESULTS WARSAW, Ind., July 12, 2011 announced today preliminary financial results for its fourth quarter and fiscal year ended
More information22 nd Annual Credit Suisse Healthcare Conference. November 12, nd Annual Credit Suisse Healthcare Conference November 12, 2013.
22 nd Annual Credit Suisse Healthcare Conference November 12, 2013 1 Safe Harbor For Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of
More informationThe Corporate Executive Board Company Reports Second Quarter Results and Raises 2012 Non-GAAP Diluted Earnings Per Share and Adjusted EBITDA Guidance
Contact: Richard S. Lindahl Chief Financial Officer 1919 North Lynn Street (571) 303-6956 Arlington, Virginia 22209 jconnor@executiveboard.com www.exbd.com The Corporate Executive Board Company Reports
More information36 th Annual J.P. Morgan Healthcare Conference. January 10, 2018
36 th Annual J.P. Morgan Healthcare Conference January 10, 2018 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute forward-looking statements,
More informationTransUnion. Investor Presentation
TransUnion Investor Presentation APRIL 2017 Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
More informationEXPEDIA AGREES TO ACQUIRE HOMEAWAY NOVEMBER 2015
EXPEDIA AGREES TO ACQUIRE HOMEAWAY NOVEMBER 2015 Safe Harbor and Other Information Forward-Looking Statements. This presentation contains "forward-looking statements" within the meaning of the Private
More informationCautionary Statement Regarding Forward-Looking Information
Ecolab 1 Fourth Quarter 2011 Teleconference Supplemental Data Cautionary Statement Cautionary Statement Regarding Forward-Looking Information This communication contains various "Forward-Looking Statements"
More informationinvestmnt Conference August 5, 2015 Susie Lisa, CFA Vice President, Investor Relations
investmnt Conference August 5, 2015 Susie Lisa, CFA Vice President, Investor Relations 1 Safe harbor for forward-looking statements and Disclaimers This presentation contains forward-looking statements
More informationFourth Quarter Fiscal Year 2017
Fourth Quarter Fiscal Year 2017 October 25, 2017 J. Michael Bruff Vice President Investor Relations Mike.Bruff@Varian.com This presentation is intended exclusively for investors. It is not intended for
More informationTENNANT COMPANY. INVESTOR PRESENTATION Second Quarter 2018 REINVENTING HOW THE WORLD CLEANS
INVESTOR PRESENTATION Second Quarter 2018 REINVENTING HOW THE WORLD CLEANS 2 Safe Harbor Statement This presentation contains certain statements that are considered forward-looking statements within the
More informationBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2007
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2007 Natick, MA (April 23, 2007) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter
More informationDJO Global, Inc. Company Presentation. June 2013
DJO Global, Inc. Company Presentation June 2013 Safe Harbor Statement This presentation has been prepared by DJOFL. The information contained in this presentation is for information purposes only. The
More informationZimmer Biomet Holdings, Inc. 3rd Quarter 2017 Earnings Call Presentation. November 1, 2017
Zimmer Biomet Holdings, Inc. 3rd Quarter 2017 Earnings Call Presentation November 1, 2017 Cautionary Note on Forward-Looking Statements and Non- GAAP Financial Measures Our discussions during this presentation
More informationThis presentation for Loblaw Companies Limited ( Loblaw ) and Shoppers Drug Mart Corporation ( Shoppers Drug Mart ) contains forward-looking statement
1 This presentation for Loblaw Companies Limited ( Loblaw ) and Shoppers Drug Mart Corporation ( Shoppers Drug Mart ) contains forward-looking statements about the proposed acquisition by Loblaw of all
More informationCIGNA CORPORATION INVESTOR PRESENTATION. May 5, Cigna
CIGNA CORPORATION INVESTOR PRESENTATION May 5, 2017 1 Forward looking statements CAUTIONARY STATEMENT FOR PURPOSES OF THE SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
More informationCatalent to Acquire Cook Pharmica. September 19, 2017
Catalent to Acquire Cook Pharmica September 19, 2017 Disclaimer Statement Forward-Looking Statements This release contains both historical and forward-looking statements, including concerning the closing
More informationJefferies 2014 Global Healthcare Conference
Jefferies 2014 Global Healthcare Conference June 4 th, 2014 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. This includes
More informationSTRATEGIC PARTNERSHIP WITH ALTRIA TO ACCELERATE GROWTH AND INNOVATION
NASDAQ / TSX TICKER CRON STRATEGIC PARTNERSHIP WITH ALTRIA TO ACCELERATE GROWTH AND INNOVATION December 2018 Disclaimers & Cautionary Statements C R O N O S G R O U P INC. This communication contains forward-looking
More informationWaters Corporation Management Presentation. July 2018
Waters Corporation Management Presentation July 2018 Cautionary Statements This presentation may contain forward-looking statements regarding future results and events. For this purpose, any statements
More informationJune Dear Fellow Takeda Shareholder,
June 2018 Dear Fellow Takeda Shareholder, Since joining Takeda in April 2014, my mission has been to continue the transformation of Takeda in order to ensure that Takeda will be a successful company in
More informationTENNANT COMPANY INVESTOR PRESENTATION REINVENTING HOW THE WORLD CLEANS
INVESTOR PRESENTATION REINVENTING HOW THE WORLD CLEANS 2 Safe Harbor Statement This presentation contains certain statements that are considered forward-looking statements within the meaning of the Private
More informationQ Financial Results. February 26, 2018
Q4 2017 Financial Results February 26, 2018 Forward Looking Statements & Non-GAAP Financial Measures Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationIntuitive Surgical Announces Third Quarter Earnings
Intuitive Surgical Announces Third Quarter Earnings October 18, SUNNYVALE, Calif., Oct. 18, (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. ( Intuitive ) (Nasdaq: ISRG), a global technology leader in roboticassisted,
More informationInvestor Presentation January 2018
Investor Presentation January 2018 2 Forward-looking Information This presentation contains forward-looking information within the meaning of applicable securities laws. Forward-looking information may
More informationRaymond James 37 th Annual Institutional Investors Conference. March 8, 2016
Raymond James 37 th Annual Institutional Investors Conference March 8, 2016 Forward-looking statements and Non-GAAP financial measures Forward-looking statements Certain statements included in this presentation,
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Alistair Macdonald Chief Executive Officer January 8, 2019 Forward-Looking Statements, Non-GAAP Financial Measures, and Basis of Financial Presentation Forward-Looking
More informationFinancial Targets through 2022: Focus on Value Creation
Financial Targets through 2022: Focus on Value Creation /////////// Capital Markets Day London, December 5, 208 Wolfgang Nickl CFO Bayer AG Disclaimer Cautionary Statements Regarding Forward-Looking Information
More informationUSF SMIF Price Intrinsic Value Target Price
USF SMIF Price Intrinsic Value Target Price Recommendation BUY 656.75 754.42 840.70 Analysts: A. Nader, J. Ortiz, L. Arruda GICS Sector Healthcare Sub-Industry Health Care Equipment Summary This company
More informationTENNANT COMPANY. INVESTOR PRESENTATION Third Quarter 2018 REINVENTING HOW THE WORLD CLEANS
INVESTOR PRESENTATION Third Quarter 2018 REINVENTING HOW THE WORLD CLEANS 2 Safe Harbor Statement This presentation contains certain statements that are considered forward-looking statements within the
More informationTeva Pharmaceutical Industries Ltd. Q August 2, 2018
Teva Pharmaceutical Industries Ltd. Q2 2018 August 2, 2018 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private
More informationFourth Quarter 2017 Earnings Conference Call
Fourth Quarter 2017 Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer February 8, 2018 Important Information No Offer
More information34 th Annual J.P. Morgan Healthcare Conference. Steve Collis, President & CEO Tim Guttman, EVP & CFO
34 th Annual J.P. Morgan Healthcare Conference Steve Collis, President & CEO Tim Guttman, EVP & CFO January 12, 2016 Steve Collis President & CEO Cautionary Note Regarding Forward-Looking Statements Certain
More informationQ4 & Full Year FY2018 Financial Results. November 6, 2018
Q4 & Full Year FY2018 Financial Results November 6, 2018 Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are forward-looking statements within
More informationBank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO
Bank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements other than
More informationOur Transformation Continues. March 21, 2018
Our Transformation Continues March 21, 2018 Disclosure Regarding Forward-Looking Statements Forward-Looking Statements and Factors That May Affect Future Results: Throughout this presentation, we make
More informationWaters Corporation Management Presentation
Waters Corporation Management Presentation Chris O Connell Chairman & Chief Executive Officer January 2019 Cautionary Statements This presentation may contain forward-looking statements regarding future
More informationNU SKIN ENTERPRISES REPORTS RECORD FOURTH-QUARTER AND 2010 RESULTS
FOR IMMEDIATE RELEASE CONTACTS: Investors Scott Pond, (801) 345-2657, spond@nuskin.com Media Kara Schneck, (801) 345-2116, kschneck@nuskin.com NU SKIN ENTERPRISES REPORTS RECORD FOURTH-QUARTER AND 2010
More informationCreating Value by Accelerating Transformation & Growth
Creating Value by Accelerating Transformation & Growth Univar Announces Agreement to Acquire Nexeo September 17, 2018 1 2018 Univar, Inc. All rights reserved. Forward-Looking Statements This communication
More informationCONSOLIDATED FINANCIAL STATEMENTS
FINANCIAL TABLE OF CONTENTS 2 Management s discussion and analysis of financial condition and results of operations 23 Consolidated statements of operations 2003 CONSOLIDATED FINANCIAL STATEMENTS 24 Consolidated
More informationIQVIA Reports Third-Quarter 2018 Results and Updates Full-Year 2018 Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More informationFor personal use only. LifeHealthcare Group Limited M4 Healthcare Pty Limited Acquisition Briefing 25 May 2015
LifeHealthcare Group Limited M4 Healthcare Pty Limited Acquisition Briefing 25 May 2015 Agenda Transaction Highlights and Overview Strategic Rationale Overview of M4 Business Transaction Highlights LifeHealthcare
More informationIntuitive Surgical Announces Fourth Quarter Earnings
Intuitive Surgical Announces Fourth Quarter Earnings January 25, 2018 SUNNYVALE, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (NASDAQ:ISRG), a global technology leader in robotic-assisted,
More informationAcquisition of Generic Drug-Related Assets of Citron Pharma and Lucid Pharma
NASDAQ: ACET ACETO Corporation Acquisition of Generic Drug-Related Assets of Citron Pharma and Lucid Pharma November 3, 2016 Disclosure This presentation contains forward-looking statements, as defined
More informationZimmer Biomet Holdings, Inc. 1 st Quarter 2018 Earnings Call Presentation. April 26, 2018
Zimmer Biomet Holdings, Inc. 1 st Quarter 2018 Earnings Call Presentation April 26, 2018 Cautionary Note on Forward-Looking Statements and Non- GAAP Financial Measures Cautionary Note on Forward-Looking
More informationOur Transformation Continues Sidoti NDR May 29-30, 2018
Our Transformation Continues Sidoti NDR May 29-30, 2018 Disclosure Regarding Forward-Looking Statements Forward-Looking Statements and Factors That May Affect Future Results: Throughout this presentation,
More informationNEOVASC INC. REPORTS FINANCIAL RESULTS FOR 2013
NEWS RELEASE TSX Venture Exchange: NVC NEOVASC INC. REPORTS FINANCIAL RESULTS FOR 2013 --2013 A Year of Transition as Tiara TM Transcatheter Mitral Valve Replacement Device and Neovasc Reducer TM for Refractory
More informationJ.P. MORGAN HEALTHCARE CONFERENCE. Joe Woody Chief Executive Officer
J.P. MORGAN HEALTHCARE CONFERENCE Joe Woody Chief Executive Officer 0 OVERVIEW FORWARD-LOOKING INFORMATION Certain matters in this presentation and webcast, including our outlook, expectations and planning
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers Baird Industrial Conference, November 2017 Matthijs Glastra, Chief Executive Officer NASDAQ: NOVT 1 Safe Harbor Statement
More informationBOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2017
FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2017 Marlborough, Mass. (January 9, 2018) -- Boston Scientific Corporation
More informationDJO Incorporated Announces Financial Results for Third Quarter 2006
Announces Financial Results for Third Quarter 2006 -- Record Third Quarter 2006 Net Revenues of $113.2 Million Exceed Expectations -- SAN DIEGO--(BUSINESS WIRE)--Nov. 2, 2006--, (NYSE:DJO), a global provider
More informationNU SKIN ENTERPRISES REPORTS RECORD FIRST-QUARTER REVENUE AND RAISES ANNUAL GUIDANCE
FOR IMMEDIATE RELEASE CONTACTS: Investors Scott Pond (801) 345-2657, spond@nuskin.com Media Kara Schneck (801) 345-2116, kschneck@nuskin.com NU SKIN ENTERPRISES REPORTS RECORD FIRST-QUARTER REVENUE AND
More informationAcquisition of PARAGARD IUD from Teva September 11, 2017
Acquisition of PARAGARD IUD from Teva Forward Looking Statements Forward Looking Statements This earnings release contains "forward looking statements" as defined by the Private Securities Litigation Reform
More informationPhilips Healthcare Financial Update. Ingo Bank, CFO Philips Healthcare
Philips Healthcare Financial Update Ingo Bank, CFO Philips Healthcare Key takeaways Growth outlook: Slow start into first half of 2013 Solid outlook for growth geographies North America market challenging
More informationFOSSIL GROUP, INC. REPORTS FIRST QUARTER 2018 RESULTS. First Quarter Net Sales of $569 million; Diluted EPS (Loss) of $(0.99)
FOSSIL GROUP, INC. REPORTS FIRST QUARTER RESULTS First Quarter Net Sales of $569 million; Diluted EPS (Loss) of $(0.99) Provides Second Quarter Guidance and Updates Fiscal Guidance Richardson, TX. May
More informationMcGraw Hill Financial to Acquire SNL Financial
McGraw Hill Financial to Acquire SNL Financial Complementary data and analytics business expected to accelerate growth, increase margins, deepen product offerings, and expand global reach MHFI s 2Q earnings
More informationSTRYKER. Kevin A. Lobo, President & Chief Executive Officer
STRYKER Kevin A. Lobo, President & Chief Executive Officer January 15, 2014 FORWARD LOOKING STATEMENT Certain statements made in the presentation may contain information that includes or is based on forward-looking
More informationInvestor Introduction & Discussion. October 2018
Investor Introduction & Discussion October 2018 Table of Contents Introduction to Harvard Bioscience 5 Strategy 8 Financial Information 20 Appendix 24 2 Safe Harbor Statement This presentation contains
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers February 2018 Matthijs Glastra, Chief Executive Officer NASDAQ: NOVT 1 Safe Harbor Statement The statements in this
More informationIQVIA Reports Second-Quarter 2018 Results and Raises Full-Year 2018 Revenue and Profit Guidance
News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports
More informationCIGNA CORPORATION. 37 th Annual J.P. Morgan Healthcare Conference January 7, David Cordani President and Chief Executive Officer
CIGNA CORPORATION 37 th Annual J.P. Morgan Healthcare Conference January 7, 2019 David Cordani President and Chief Executive Officer 2 Forward-looking statements and Non-GAAP measures CAUTIONARY STATEMENT
More informationDisclaimer / Forward Looking Statements
Disclaimer / Forward Looking Statements Statements in this presentation regarding Symmetry Medical Inc. s business, which are not historical facts, may be forward-looking statements that involve risks
More informationSECOND QUARTER 2018 EARNINGS CALL. August 7, 2018
SECOND QUARTER 2018 EARNINGS CALL August 7, 2018 1 AGENDA AND SPEAKERS Joe Woody Chief Executive Officer V NOS Outlook Update on 2018 Priorities Steve Voskuil Chief Financial Officer Second Quarter Financial
More informationRaymond James Institutional Investor Conference
Raymond James Institutional Investor Conference Marc Naughton Executive Vice President and Chief Financial Officer March 7, 2017 Cautionary Statement Regarding Forward-Looking Statements This presentation
More informationQ Earnings Call
We make healthy possible Q3 2018 Earnings Call Financial Results and Business Update November 7, 2018 Safe Harbor Statement & Non-GAAP Financial Measures Safe Harbor Statement Certain statements contained
More informationForward Looking Statements and Non-GAAP Measures Caution Regarding Forward-Looking Statements
Ravi Saligram, CEO Forward Looking Statements and Non-GAAP Measures Caution Regarding Forward-Looking Statements This presentation contains forward-looking statements and forward-looking information within
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Zane Burke President Marc Naughton Executive Vice President and Chief Financial Officer January 9, 2018 Cautionary Statement Regarding Forward-Looking Statements This
More informationInvestor Presentation
Investor Presentation May 2013 48,000 employees 200 offices 70 countries 1 global platform Table of Contents I. Company Description II. Global Growth Strategy III. Financial Overview IV. Appendix 2 Company
More informationDANAHER TO ACQUIRE GE LIFE SCIENCES BIOPHARMA BUSINESS ( GE Biopharma ) February 25, 2019
DANAHER TO ACQUIRE GE LIFE SCIENCES BIOPHARMA BUSINESS ( GE Biopharma ) February 25, 2019 Forward Looking Statements Statements in this presentation and the accompanying call that are not strictly historical,
More informationConsolidated Financial Statements
BOSTON SCIENTIFICAND AND SUBSIDIARIES Management s discussionand and analysis of of financial conditionand and results of of operations... 11 Management s report on on internal control over over financial
More information